Zai Lab's oncology segment is dedicated to the discovery, development, and commercialization of innovative therapies for various cancer types. This segment focuses on addressing unmet medical needs in both common and rare cancers, utilizing a combination of internal research and strategic partnerships to expand its pipeline. Key activities include preclinical studies, clinical trials (Phase 1 to Phase 3), and regulatory submissions for novel oncology drugs. The company leverages advanced technologies such as targeted therapies, immunotherapies, and antibody-drug conjugates to improve patient outcomes and overall survival rates. Zai Lab's oncology portfolio includes both internally developed candidates and in-licensed assets, positioning the company as a significant player in the rapidly evolving oncology landscape. The segment aims to provide personalized treatment options and enhance the quality of life for cancer patients.

This segment focuses on developing and commercializing therapies for autoimmune and inflammatory conditions. Zai Lab employs a multifaceted approach, including research into novel targets, development of innovative biologics and small molecules, and strategic collaborations to expand its portfolio. The company is dedicated to addressing unmet needs in diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP) and other autoimmune disorders. Research and development efforts include preclinical studies, clinical trials, and regulatory submissions. Zai Lab aims to improve patient outcomes and quality of life by providing targeted and effective treatments for autoimmune and inflammatory diseases. The segment leverages advanced technologies and methodologies to identify and develop promising therapeutic candidates.

Zai Lab's infectious diseases segment is dedicated to developing and commercializing therapies to combat serious bacterial infections. This segment focuses on addressing the growing threat of antimicrobial resistance through the development of novel antibiotics and therapeutic strategies. Key activities include preclinical research, clinical trials, and regulatory submissions for new antibacterial agents. The company's portfolio includes products like NUZYRA, which targets acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia. Zai Lab is committed to providing effective treatment options for patients with serious infections, improving patient outcomes, and contributing to the global fight against antimicrobial resistance. The segment leverages advanced technologies and methodologies to identify and develop promising therapeutic candidates.